Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Raloxifene - Usual
Raloxifene- Usual · 1 trial · 1 indication
* Recruit 300 double blind random group separated Breast Cancer LCIS patients currently using the Chemotherapy dose on Generic-1 - raloxifene (60mg x 2 orally daily), after breast tissue biopsy, to be the usual approach group. * Recruit 300 double blind random group separated Breast Cancer LCIS patients currently using the Chemotherapy dose on Generic-2 - raloxifene (60mg x 2 orally daily), after breast tissue biopsy, to be the study approach group. * Measure above every BC-LCIS patient specific Raloxifene oncology drug target ER SNP genotype in Breast Cancer cell whole genome DNA with Oxford precisely sequencing. * Report every BC-LCIS patient specific ER SNP genotype in whole genome DNA sequence.
* Recruit 300 double blind random group separated Breast Cancer LCIS patients currently using the Chemotherapy dose on Generic-1 - raloxifene (60mg x 2 orally daily), after blood draw, to be the usual approach group. * Recruit 300 double blind random group separated Breast Cancer LCIS patients currently using the Chemotherapy dose on Generic-2 - raloxifene (60mg x 2 orally daily), after blood draw, to be the study approach group. * Measure above every BC-LCIS patient specific Raloxifene oncology drug target UGT SNP genotype in WBC cell whole genome DNA with Oxford precisely sequencing. * Report every BC-LCIS patient specific UGT SNP genotype in whole genome DNA sequence.
| Arm | Type | Description |
|---|---|---|
| Raloxifene - Usual | EXPERIMENTAL | * Generic-1 - Raloxifene * Chemotherapy * Generic-1 - raloxifene hydrochloride tablet * Raloxifene 60 mg x 2 taken orally daily * Usual Approach Group (Generic-1) |
| Raloxifene - Study | EXPERIMENTAL | * Generic-2 - Raloxifene * Chemotherapy * Generic-2 - Raloxifene Hydrochloride Tablet * Raloxifene 60 mg x 2 taken orally daily * Usual Approach Group (Generic-2) |
| Name | Type | Description |
|---|---|---|
| Raloxifene - Usual | DRUG | * Generic-1 - raloxifene hydrochloride tablet * Raloxifene 60 mg x 2 taken orally daily |
| Raloxifene - Study | DRUG | * Generic-2 - Raloxifene Hydrochloride Tablet * Raloxifene 60 mg x 2 taken orally daily |
* Select 600 Breast Cancer LCIS Patients who are suitable for breast tissue biopsy * High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) * Dosage Duration at least 90 days * The usual approach group - Recruit 300 double blind random group sepa...
Top 20 of 92 competitors
Raloxifene - Usual is an investigational small molecule being studied for use in breast cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in a controlled, randomized, double-blind clinical trial enrolling 600 female participants in the United States.
Raloxifene - Usual is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker DSGN. The company is conducting a Phase 2 clinical trial of the drug for breast cancer.
Raloxifene - Usual is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants.
Raloxifene - Usual is being studied in one active Phase 2 clinical trial with the identifier NCT06062810. The trial, titled "Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms," is enrolling 600 female participants with breast cancer in the United States.
Yes, Raloxifene - Usual is also known as Raloxifene - Usual. Both names refer to the same investigational drug being developed by Design Therapeutics, Inc. for the treatment of breast cancer.